
EP WIRE on Management of ventricular tachycardia – antiarrhythmic drugs, catheter ablation, ICD therapies


Q1 Is your institution:



| Answer Choices | Responses | |
|-----------------------------------|-----------|----|
| A university hospital (academic) | 84.85% | 28 |
| A private hospital (non-academic) | 9.09% | 3 |
| Other type of hospital | 6.06% | 2 |
| Total | | 33 |


Q4 Would you be comfortable if we acknowledge your centre in the Europace Journal and on the Website?





| Answer Choices | Responses |
|----------------|-------------------|
| Yes | 100.00% 33 |
| No | 0.00% |
| Total | 33 |


Q5 How many VT patients do you treat in your centre (including treatments of AADs, ICD and ablation)?



| Answer Choices | Responses | |
|----------------|-----------|----|
| None | 0.00% | 0 |
| <50 / year | 9.09% | 3 |
| 50-100 / year | 30.30% | 10 |
| 100-200 / year | 30.30% | 10 |
| 200-400 / year | 15.15% | 5 |
| >400/ year | 15.15% | 5 |
| Total | | 33 |


Q6 How many ICD did you implant in your centre in the last calendar year?

Answered: 33 Skipped: 1



| Answer Choices | Responses | |
|----------------|-----------|----|
| None | 0.00% | 0 |
| <20 | 3.03% | 1 |
| 20-50 | 15.15% | 5 |
| 50-100 | 18.18% | 6 |
| 100-200 | 51.52% | 17 |
| >200 | 12.12% | 4 |
| Total | | 33 |


Q7 How many VT ablation procedures did you perform in your centre in the last calendar year?



| Answer Choices | Responses | |
|----------------|-----------|----|
| None | 6.06% | 2 |
| <20 | 30.30% | 10 |
| 20-50 | 45.45% | 15 |
| 50-100 | 12.12% | 4 |
| 100-200 | 6.06% | 2 |
| >200 | 0.00% | 0 |
| Total | | 33 |


Q8 What is the distribution of etiologies of sustained VT in your centre? Please indicate percentage (total 100%).

Answered: 31 Skipped: 3




| Answer Choices | Average Number | Total Number | Responses |
|-----------------------------|----------------|--------------|-----------|
| Coronary artery disease | 58 | 1,802 | 31 |
| Non-ischemic cardiomyopathy | 22 | 679 | 31 |
| Channelopathy | 5 | 157 | 31 |
| Idiopathic | 11 | 342 | 31 |
| others | 3 | 104 | 31 |
| Total Respondents: 31 | | | |

Q9 Which examinations do you perform in different patients after the first VT episode is documented? (multiple choices allowed)




EP WIRE on Management of ventricular tachycardia – antiarrhythmic drugs, catheter ablation, ICD therapies




| | Monomorphic VT with ischemic heart disease | Polymorphic VT with ischemic heart disease | Other VTs | Total Respondents |
|----------------------------|--|--|--------------|----------------------|
| Transthoracic | 96.77% | 93.55% | 90.32% | |
| echocardiography | 30 | 29 | 28 | 31 |
| Exercise test | 39.29% | 39.29% | 89.29% | |
| | 11 | 11 | 25 | 28 |
| Coronary angiography | 93.55% | 96.77% | 61.29% | |
| | 29 | 30 | 19 | 31 |
| MRI | 46.43% | 39.29% | 89.29% | |
| | 13 | 11 | 25 | 28 |
| Electrophysiological study | 62.50% | 37.50% | 91.67% | |
| | 15 | 9 | 22 | 24 |
| Signal-averaged ECG | 33.33% | 41.67% | 83.33% | |
| | 4 | 5 | 10 | 12 |
| Myocardial biopsy | 0.00% | 0.00% | 100.00% | |
| | 0 | 0 | 9 | 9 |
| Genetic test | 11.76% | 29.41% | 82.35% | |
| | 2 | 5 | 14 | 17 |

Q10 What is the purpose of invasive electrophysiological study if a clinical sustained VT is documented by ECG? (Multiple choices allowed)




| Answer Choices | Responses | |
|--|-----------|----|
| To evaluate ventricular electrical instability | 22.58% | 7 |
| To decide the strategy of treatment | 54.84% | 17 |
| To test the efficacy of antiarrhythmic drugs | 9.68% | 3 |
| To optimize ICD programing | 9.68% | 3 |
| I will not perform electrophysiological study | 45.16% | 14 |
| Total Respondents: 31 | | |

Q11 What is the first choice of antiarrhythmic drugs to prevent recurrent hemodynamically stable VTs (ICD will be additionally implanted if there is indication)?




| | Beta- blocker | Ca- channel blocker | Flecainide | Amiodarone | Sotalol | Disopyramide | Other | None | Total | Weighted Average |
|---|------------------|---------------------------|------------|------------|---------|--------------|--------|--------|-------|---------------------|
| Idiopathic VT | 77.42% | 9.68% | 9.68% | 0.00% | 0.00% | 0.00% | 0.00% | 3.23% | | |
| | 24 | 3 | 3 | 0 | 0 | 0 | 0 | 1 | 31 | 1.52 |
| VT with ischemic | 58.06% | 0.00% | 0.00% | 41.94% | 0.00% | 0.00% | 0.00% | 0.00% | | |
| heart disease | 18 | 0 | 0 | 13 | 0 | 0 | 0 | 0 | 31 | 2.26 |
| VT with dilated | 40.00% | 0.00% | 0.00% | 56.67% | 3.33% | 0.00% | 0.00% | 0.00% | | |
| cardiomyopathy | 12 | 0 | 0 | 17 | 1 | 0 | 0 | 0 | 30 | 2.83 |
| VT with | 67.74% | 0.00% | 0.00% | 25.81% | 0.00% | 3.23% | 0.00% | 3.23% | | |
| nypertrophic cardiomyopathy | 21 | 0 | 0 | 8 | 0 | 1 | 0 | 1 | 31 | 2.16 |
| VT with | 58.06% | 0.00% | 3.23% | 16.13% | 22.58% | 0.00% | 0.00% | 0.00% | | |
| Arrhythmogenic right ventricular cardiomyopathy | 18 | 0 | 1 | 5 | 7 | 0 | 0 | 0 | 31 | 2.45 |
| VT with Brugada | 35.48% | 0.00% | 0.00% | 3.23% | 3.23% | 3.23% | 25.81% | 29.03% | | |
| syndrome | 11 | 0 | 0 | 1 | 1 | 1 | 8 | 9 | 31 | 4.97 |
| Catecholaminergic | 93.55% | 0.00% | 3.23% | 0.00% | 0.00% | 0.00% | 3.23% | 0.00% | | |
| polymorphic VT | 29 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 31 | 1.26 |

Q12 If an antiarrhythmic drug (AAD) is prescribed to a patient due to recurrent VT, how do you test the efficacy of the drug? (multiple choice allowed)




| Answer Choices | Responses | |
|--|-----------|----|
| Programmed electrical stimulation | 6.67% | 2 |
| Exercise test only | 33.33% | 10 |
| Holter monitoring | 60.00% | 18 |
| Implantable loop recording | 10.00% | 3 |
| Clinical follow-up only | 56.67% | 17 |
| If the patient has ICD, interrogate the device | 90.00% | 27 |
| Total Respondents: 30 | | |


Q13 Which therapeutic options do you choose for recurrent sustained monomorphic VT in different patients if hemodynamically stable? Please rank with number 1, 2 and 3 as first, second and third choice, respectively. Please choose 0 if alternative is not an option.



EP WIRE on Management of ventricular tachycardia – antiarrhythmic drugs, catheter ablation, ICD therapies



EP WIRE on Management of ventricular tachycardia – antiarrhythmic drugs, catheter ablation, ICD therapies




| | 0 | 1 | 2 | 3 | Total |
|---|-------|--------|--------|--------|-------|
| Post myocardial infarction LVEF ≤35% | 3.33% | 6.67% | 66.67% | 23.33% | |
| | 1 | 2 | 20 | 7 | |
| Post myocardial infarction LVEF normal | 0.00% | 46.67% | 36.67% | 16.67% | |
| | 0 | 14 | 11 | 5 | |
| Non-ischemic cardiomyopathy LVEF ≤35% | 3.45% | 10.34% | 68.97% | 17.24% | |
| | 1 | 3 | 20 | 5 | |
| Non-ischemic cardiomyopathy LVEF normal | 0.00% | 50.00% | 43.33% | 6.67% | |
| | 0 | 15 | 13 | 2 | |
| Idiopathic | 3.33% | 46.67% | 46.67% | 3.33% | |
| · | 1 | 14 | 14 | 1 | |


EP WIRE on Management of ventricular tachycardia – antiarrhythmic drugs, catheter ablation, ICD therapies

| | 0 | 1 | 2 | 3 | Total |
|---|--------|--------|--------|--------|-------|
| Post myocardial infarction LVEF ≤35% | 3.33% | 93.33% | 3.33% | 0.00% | |
| | 1 | 28 | 1 | 0 | 3 |
| Post myocardial infarction LVEF normal | 13.79% | 17.24% | 31.03% | 37.93% | |
| | 4 | 5 | 9 | 11 | 2 |
| Non-ischemic cardiomyopathy LVEF ≤35% | 3.33% | 90.00% | 6.67% | 0.00% | |
| | 1 | 27 | 2 | 0 | 3 |
| Non-ischemic cardiomyopathy LVEF normal | 13.79% | 24.14% | 20.69% | 41.38% | |
| | 4 | 7 | 6 | 12 | 2 |
| Idiopathic | 41.38% | 6.90% | 3.45% | 48.28% | |
| | 12 | 2 | 1 | 14 | : |
| lation | | | | | |
| | 0 | 1 | 2 | 3 | Total |
| Post myocardial infarction LVEF ≤35% | 0.00% | 6.67% | 30.00% | 63.33% | |
| | 0 | 2 | 9 | 19 | ; |
| Post myocardial infarction LVEF normal | 0.00% | 40.00% | 33.33% | 26.67% | |
| | 0 | 12 | 10 | 8 | (|
| Non-ischemic cardiomyopathy LVEF ≤35% | 3.45% | 3.45% | 20.69% | 72.41% | |
| | 1 | 1 | 6 | 21 | : |
| Non-ischemic cardiomyopathy LVEF normal | 6.90% | 27.59% | 31.03% | 34.48% | |
| | 2 | 8 | 9 | 10 | : |
| Idiopathic | 6.67% | 43.33% | 46.67% | 3.33% | |
| | 2 | 13 | 14 | 1 | |


Q14 How do you manage recurrent symptomatic non-sustained monomorphic VT in different patients if hemodynamically stable? Please rank with number 1, 2 and 3 as first, second and third choice, respectively. Please choose 0 if alternative is not an option.



EP WIRE on Management of ventricular tachycardia – antiarrhythmic drugs, catheter ablation, ICD therapies



EP WIRE on Management of ventricular tachycardia – antiarrhythmic drugs, catheter ablation, ICD therapies




| | 0 | 1 | 2 | 3 | Total |
|---|--------|--------|--------|-------|-------|
| Post myocardial infarction LVEF ≤35% | 10.00% | 20.00% | 66.67% | 3.33% | |
| | 3 | 6 | 20 | 1 | |
| Post myocardial infarction LVEF normal | 10.00% | 70.00% | 20.00% | 0.00% | |
| | 3 | 21 | 6 | 0 | |
| Non-ischemic cardiomyopathy LVEF ≤35% | 3.33% | 23.33% | 70.00% | 3.33% | |
| | 1 | 7 | 21 | 1 | |
| Non-ischemic cardiomyopathy LVEF normal | 6.67% | 80.00% | 13.33% | 0.00% | |
| | 2 | 24 | 4 | 0 | |
| Idiopathic | 10.00% | 60.00% | 30.00% | 0.00% | |
| | 3 | 18 | 9 | 0 | |


EP WIRE on Management of ventricular tachycardia – antiarrhythmic drugs, catheter ablation, ICD therapies

| | 0 | 1 | 2 | 3 | Total |
|---|--------|--------|--------|--------|-------|
| Post myocardial infarction LVEF ≤35% | 6.67% | 70.00% | 6.67% | 16.67% | |
| | 2 | 21 | 2 | 5 | ; |
| Post myocardial infarction LVEF normal | 43.33% | 3.33% | 23.33% | 30.00% | |
| | 13 | 1 | 7 | 9 | ; |
| Non-ischemic cardiomyopathy LVEF ≤35% | 6.67% | 70.00% | 6.67% | 16.67% | |
| | 2 | 21 | 2 | 5 | ; |
| Non-ischemic cardiomyopathy LVEF normal | 53.57% | 3.57% | 21.43% | 21.43% | |
| | 15 | 1 | 6 | 6 | |
| Idiopathic | 65.52% | 0.00% | 0.00% | 34.48% | |
| | 19 | 0 | 0 | 10 | |
| olation | | | | | |
| | 0 | 1 | 2 | 3 | Total |
| Post myocardial infarction LVEF ≤35% | 26.67% | 6.67% | 20.00% | 46.67% | |
| | 8 | 2 | 6 | 14 | |
| Post myocardial infarction LVEF normal | 26.67% | 16.67% | 30.00% | 26.67% | |
| | 8 | 5 | 9 | 8 | |
| Non-ischemic cardiomyopathy LVEF ≤35% | 26.67% | 3.33% | 16.67% | 53.33% | |
| | 8 | 1 | 5 | 16 | |
| Non-ischemic cardiomyopathy LVEF normal | 24.14% | 13.79% | 41.38% | 20.69% | |
| | 7 | 4 | 12 | 6 | |
| Idiopathic | 10.00% | 40.00% | 50.00% | 0.00% | |
| | 3 | 12 | 15 | 0 | |


Q15 How do you manage recurrent polymorphic VT in different patients if hemodynamically unstable? Please rank with number 1, 2 and 3 as first, second and third choice, respectively. Please choose 0 if alternative is not an option.



EP WIRE on Management of ventricular tachycardia – antiarrhythmic drugs, catheter ablation, ICD therapies



EP WIRE on Management of ventricular tachycardia – antiarrhythmic drugs, catheter ablation, ICD therapies




| | 0 | 1 | 2 | 3 | Total |
|---|-------|--------|--------|-------|-------|
| Post myocardial infarction LVEF ≤35% | 6.90% | 13.79% | 75.86% | 3.45% | |
| · | 2 | 4 | 22 | 1 | |
| Post myocardial infarction LVEF normal | 6.67% | 40.00% | 50.00% | 3.33% | |
| | 2 | 12 | 15 | 1 | |
| Non-ischemic cardiomyopathy LVEF ≤35% | 6.90% | 13.79% | 79.31% | 0.00% | |
| | 2 | 4 | 23 | 0 | |
| Non-ischemic cardiomyopathy LVEF normal | 6.90% | 44.83% | 41.38% | 6.90% | |
| | 2 | 13 | 12 | 2 | |
| | , | | | | |
| | 0 | 1 | 2 | 3 | Total |

EP WIRE on Management of ventricular tachycardia – antiarrhythmic drugs, catheter ablation, ICD therapies

| Post myocardial infarction LVEF ≤35% | 6.67% | 80.00% | 13.33% | 0.00% | |
|---|--------|--------|--------|--------|-------|
| | 2 | 24 | 4 | 0 | 30 |
| Post myocardial infarction LVEF normal | 20.00% | 53.33% | 23.33% | 3.33% | |
| | 6 | 16 | 7 | 1 | 30 |
| Non-ischemic cardiomyopathy LVEF ≤35% | 6.67% | 80.00% | 10.00% | 3.33% | |
| | 2 | 24 | 3 | 1 | 30 |
| Non-ischemic cardiomyopathy LVEF normal | 30.00% | 50.00% | 16.67% | 3.33% | |
| | 9 | 15 | 5 | 1 | 30 |
| ation | | | | | |
| | 0 | 1 | 2 | 3 | Total |
| Post myocardial infarction LVEF ≤35% | 37.93% | 6.90% | 10.34% | 44.83% | |
| | 11 | 2 | 3 | 13 | 29 |
| Post myocardial infarction LVEF normal | 40.00% | 3.33% | 10.00% | 46.67% | |
| | 12 | 1 | 3 | 14 | 30 |
| Non-ischemic cardiomyopathy LVEF ≤35% | 37.93% | 6.90% | 3.45% | 51.72% | |
| | 11 | 2 | 1 | 15 | 29 |
| Non-ischemic cardiomyopathy LVEF normal | 41.38% | 6.90% | 13.79% | 37.93% | |
| | 12 | 2 | 4 | 11 | 29 |
| | | | | | |


Q16 Do you withdraw antiarrhythmic drugs before VT ablation procedure?






| Answer Choices | Responses |
|---|-----------|
| Yes always | 13.33% |
| Yes, except for Amiodarone | 13.33% |
| No | 6.67% |
| Depending on type of VT and presence of heart disease | 66.67% |
| Total | 3 |

Q17 In which situation would you refer a post-myocardial-infarction patient to catheter ablation if the patient has VT after ICD implantation?




| nswer Choices | Responses | |
|---|-----------|----|
| Recurrent hemodynamically unstable VT | 6.67% | 2 |
| Recurrent VT, irrespective hemodynamically response | 26.67% | 8 |
| Frequent shocks due to VTs | 36.67% | 11 |
| After the first shock due to VT | 13.33% | 4 |
| After failure of amiodarone | 16.67% | 5 |
| Never | 0.00% | 0 |
| tal | | 30 |

Q18 Which techniques do you employ for ablation of scar-related VT? (Multiple choices allowed)



| Answer Choices | Responses | |
|--|-----------|----|
| Excitation analysis to find the earliest activation during VT | 43.33% | 13 |
| Excitation analysis to find mid-diastolic potentials during VT | 76.67% | 23 |
| Entrainment analysis | 66.67% | 20 |
| Substrate mapping during sinus rhythm | 83.33% | 25 |
| Pace mapping of QRS morphologies | 66.67% | 20 |
| I do not perform VT ablation | 10.00% | 3 |
| Total Respondents: 30 | | |


Q19 When do you perform epicardial VT ablation in patients with structural heart disease?



| swer Choices | | |
|---|--------|----|
| Epicardial approach is applied only after failure of endocardial approach | 43.33% | 13 |
| Endocardial and epicardial approach at the first procedure | 16.67% | 5 |
| I do not perform epicardial VT ablation | 30.00% | 9 |
| I do not perform VT ablation | 10.00% | 3 |
| otal | | 30 |

Q20 What is the endpoint of VT ablation procedure in your centre?






| | Termination of clinical VT during ablation | Non-inducibility of VT | Modification of substrate | Others | Total Respondents |
|-------------------------------------|--|------------------------|---------------------------|----------------|----------------------|
| Idiopathic VT | 33.33% 8 | 70.83% 17 | 0.00% 0 | 12.50% | 24 |
| Post myocardial infarction VT | 29.17% 7 | 79.17% 19 | 58.33% | 8.33% 2 | 24 |
| VT with non-ischemic cardiomyopathy | 25.00% 6 | 83.33% 20 | 50.00% 12 | 8.33% 2 | 24 |

Q21 Which examinations do you perform to evaluate the efficacy of catheter ablation during long-term follow-up? (Multiple choices allowed)

EP WIRE on Management of ventricular tachycardia – antiarrhythmic drugs, catheter ablation, ICD therapies




EP WIRE on Management of ventricular tachycardia – antiarrhythmic drugs, catheter ablation, ICD therapies

| | 12-lead ECG | Holter | Exercise test | Programmed electrical stimulation | Implantable loop recording | Interrogate ICD if patient has | Total Respondents |
|----------------------|----------------|--------|---------------|-----------------------------------|----------------------------|--------------------------------|----------------------|
| Idiopathic VT | 56.67% | 86.67% | 60.00% | 3.33% | 3.33% | 60.00% | |
| | 17 | 26 | 18 | 1 | 1 | 18 | 30 |
| Post myocardial | 50.00% | 63.33% | 36.67% | 6.67% | 6.67% | 93.33% | |
| infarction VT | 15 | 19 | 11 | 2 | 2 | 28 | 30 |
| VT with non-ischemic | 50.00% | 66.67% | 30.00% | 6.67% | 10.00% | 93.33% | |
| cardiomyopathy | 15 | 20 | 9 | 2 | 3 | 28 | 30 |

Q22 Do you find indications for ICD implantation in different patients with clinically documented VTs?

EP WIRE on Management of ventricular tachycardia – antiarrhythmic drugs, catheter ablation, ICD therapies




EP WIRE on Management of ventricular tachycardia – antiarrhythmic drugs, catheter ablation, ICD therapies

| | Yes | No | Depending on result of electrophysiological study | Total |
|---|---------|--------|---|-------|
| Post myocardial infarction VT LVEF ≤35% | 100.00% | 0.00% | 0.00% | |
| | 29 | 0 | 0 | 29 |
| Post myocardial infarction VT LVEF 35-40% | 68.97% | 0.00% | 31.03% | |
| | 20 | 0 | 9 | 29 |
| Post myocardial infarction VT LVEF normal | 24.14% | 34.48% | 41.38% | |
| | 7 | 10 | 12 | 29 |
| VT with non-ischemic cardiomyopathy LVEF ≤35% | 100.00% | 0.00% | 0.00% | |
| | 29 | 0 | 0 | 29 |
| VT with non-ischemic cardiomyopathy LVEF 35-40% | 65.52% | 13.79% | 20.69% | |
| | 19 | 4 | 6 | 29 |
| VT with non-ischemic cardiomyopathy LVEF normal | 27.59% | 37.93% | 34.48% | |
| | 8 | 11 | 10 | 29 |


Q23 How do you manage VT storm after ICD implantation without reversible causes?

Answered: 30 Skipped: 4



| wer Choices | Responses | |
|--|-----------|----|
| Optimize medications | 0.00% | C |
| Optimize medications first, and optimize ICD criteria for VT detection and shock | 20.00% | 6 |
| Optimize medications first, followed by catheter ablation | 76.67% | 23 |
| General anesthesia | 3.33% | |
| Overdrive pacing | 0.00% | (|
| Referral to another hospital | 0.00% | (|
| L | | 30 |

Q24 How do you treat the patients with ICD who have recurrent ventricular tachycardia or with frequent shocks during long-term follow-up?



| Answer Choices | Responses | |
|---|-----------|----|
| Optimize medications | 0.00% | 0 |
| Optimize medications first, and optimize ICD criteria for VT detection and shock. | 13.33% | 4 |
| Optimize medications first, followed by catheter ablation | 60.00% | 18 |
| Directly catheter ablation | 26.67% | 8 |
| Total | | 30 |